Patients with cancer are at increased risk for thrombotic complications, ranging from abnormal coagulation tests in the absence of clinical manifestations to deep vein thrombosis, pulmonary embolism, and fatal thromboembolism. Despite the relatively high incidence of such events, many patients with cancer are not receiving adequate anticoagulant prophylaxis and treatment.
In this educational series, a distinguished panel of faculty experts provides an in-depth review of optimal management strategies for cancer-associated venous thromboembolism (VTE), including a detailed discussion of new data on the efficacy and safety of novel oral anticoagulants. Updated evidence-based guidelines for both prevention and treatment of VTE will be discussed, as will the latest real-world data and guidance on how best to incorporate this guidance into routine practice.
Hematologists-oncologists, physicians, nurse practitioners (NPs), physician assistants (PAs), internal medicine clinicians, hospitalists, emergency department physicians, oncology nurses, and specialty pharmacists
At the conclusion of this activity, participants should be better able to:
Release: June 14, 2019
Expiration: June 14, 2020
Release: June 28, 2019
Expiration: June 28, 2020
Agency for Healthcare Research and Quality (AHQR). Preventing avoidable readmissions: improving the hospital discharge process. AHRQ website. https://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/impptdis/index.html. Updated February 2017.
Agnelli G, Becattini C, Bauersachs R, et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost. 2018;118(9):1668-1678. doi:10.1055/s-0038-1668523.
Carrier M, Lazo-Langner A, Shivakumar S, et al. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol. 2015;22(1):49-59. doi:10.3747/co.22.2392.
Expert Steering Group. Cancer-associated thrombosis (CAT), a neglected cause of cancer death: actions needed to increase health outcomes and reduce mortality. A report summarising the findings of an Expert Steering Group meeting in Belgium; December 11-12, 2015; Brussels, Belgium. https://www.anticoagulationuk.org/downloads/European%20CAT%20White%20Paper.pdf.
Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452-e466. doi:10.1016/S1470-2045(16)30369-2.
Khorana AA, Nobel S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891-1894. doi:10.1111/jth.14219.
Khorana risk score for venous thromboembolism in cancer patients. MDCalc website. https://www.mdcalc.com/khorana-risk-score-venous-thromboembolism-cancer-patients. [The Khorana risk score (calculator) was first published in 2008.]
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11(3):e442-e444. doi:10.1200/JOP.2015.004473.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cancer-associated venous thromboembolic disease. Version 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Published February 28, 2019.
National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism [NICE guideline (NG89)]. https://www.nice.org.uk/guidance/ng89. Published March 2018.
Kenneth A. Bauer, MD
Jointly provided by
These activities are supported by an educational grant from